One CRISPR treatment cut “bad” cholesterol in half for a full year

A first-in-human Phase 1 clinical trial from Cleveland Clinic found that a single infusion of a CRISPR-Cas9 gene-editing therapy produced lasting reductions in LDL (“bad”) cholesterol and triglycerides in people with lipid disorders that had not responded adequately to medications.

Click here to view the original article.